Get ready to book your GIANT Health 5000 Women early bird tickets in March! Join the 1,000s of people from all over the world that will take part in the GIANT 5000 Women global platform helping create GIANT Healthcare Impacts by taking small steps together. To find out more follow us @gianthealthevnt on Twitter
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers. …
Wearable technology that monitors our bodies can be helpful and harmful.
Wearable technology affords the opportunity to check, re-check, and check again, leading to fixation.
Read the full article in the Psychology Today blog post here.
Attendees
Sponsors and
Exhibitors
Agenda
Webinars
Contact us